AI-generated · cited to primary sources · not investment advice · How we research
Hims & Hers Health, Inc. Class A Common Stock
Our verdict on Hims & Hers Health, Inc. Class A Common Stock isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
Fund planned operations for at least the next 12 months using existing cash resources and revolving credit availability. — target: Liquidity sufficient to support operations for at least one year past the financial statement issuance date (+3 more commitments)
“We believe our existing cash resources, as well as availability under our revolving credit facility, are sufficient to support planned operations for the next 12 months. As a result, management believes that our current and available financial resources are sufficient to continue operating activities for at least one year past the issuance date of the unaudited condensed consolidated financial statements.”
Management expects personalized offerings to increasingly drive online revenue growth. (+2 more commitments)
“We expect revenue from personalized offerings, including existing and new offerings, to increasingly drive Online Revenue growth in the future.”
Reduce marketing expenses as a percentage of revenue over the long term while continuing customer acquisition investment.
“While marketing expenses may fluctuate as a percentage of revenue, we expect total marketing expenses as a percentage of revenue to continue to decrease over the long term.”
Continue investing in fulfillment, distribution, pharmacies, laboratory testing facilities, and peptide manufacturing facilities, with the goal of fulfilling a majority of pharmaceutical and over-the-counter orders through internal fulfillment capabilities. — target: Fulfill a majority of pharmaceutical and OTC customer orders internally (+4 more commitments)
“We intend to continue to invest in our fulfillment, distribution, and operating capabilities, including in our wholly-owned pharmacies... our laboratory testing facilities and our peptide manufacturing facility... with the goal of fulfilling a majority of our pharmaceutical and over-the-counter customer orders through internal fulfillment capabilities. For example, we are making investments in the expansion of our current Facilities, which are expected to continue for at least the next 12 months.”
Management expects to continue significant marketing investment to acquire new customers. (+1 more commitment)
“Additionally, we expect to continue to make significant investments in marketing to acquire new customers and we expect to continue to make investments in product offerings and customer experience.”
See the full cited Management analysis of Hims & Hers Health, Inc. Class A Common Stock
How durable is the business?
Liquidity expanded dramatically after the issuance of zero-coupon convertible notes and the buildup of investments. The company had ample liquidity and no revolving-credit borrowings, but leverage increased through approximately $1 billion of convertible-note principal. (1 expanding, 2 shifted)
“As of June 30, 2026, our principal sources of liquidity totaled $841.0 million... We believe our existing cash resources, as well as availability under our revolving credit facility, are sufficient to support planned operations for the next 12 months.”
Online revenue remained the dominant business stream and accelerated materially. It grew 50% year over year in Q3 FY25 and 76% for the first nine months, while personalized offerings rose to approximately 70% of online revenue from about 50% previously. This represents both strong revenue expansion and a favorable shift toward personalized, recurring treatment plans. (3 expanding, 2 contracting across 1 engine)
“Revenue was $753.2 million for the three months ended June 30, 2026, compared to $544.8 million for the three months ended June 30, 2025, an increase of $208.4 million, or 38%... Our consolidated revenue primarily comprises online sales of health and wellness products through our websites and mobile applications, including prescription and non-prescription products, as well as services, primarily consisting of medical consultation services, membership-based access, post-consultation service support, and delivery of laboratory testing results... Gross margin was 64% for the three months ended June 30, 2026, compared to 76% for the three months ended June 30, 2025.”
The cost-advantage strategy shifted from an intended future benefit to a heavy current investment cycle. Internal fulfillment and manufacturing assets expanded substantially, but free cash flow fell sharply because capital spending rose faster than operating cash flow. (2 shifted)
“Free Cash Flow $59,984... compared to $138,834... Our purchases of property, equipment, and intangible assets have increased in recent quarters as we scale our internal fulfillment capabilities to supply the increasing demand for our personalized offerings.”
The U.S. weight-loss model shifted in nature: Hims & Hers moved toward branded GLP-1 access, limited compounded GLP-1 access, and a separate recurring membership fee. This is a business-model shift rather than a simple volume increase, with potential revenue-quality benefits from membership recurrence but near-term customer-retention and margin risk. (1 shifted)
“At the end of March 2026, we launched a membership program for our weight loss offerings... Memberships auto-renew monthly and must be active for customers to obtain weight loss medications through a separate Subscription.”
The economics of the core online stream weakened in the latest quarter despite strong sales growth. Gross margin fell as newer offerings carried higher product, packaging, shipping, and fulfillment costs, particularly offerings with shorter shipment cadences. (3 contracting, 1 expanding)
“Correspondingly, gross margin was 74% for the three months ended September 30, 2025, compared to 79% for the three months ended September 30, 2024... These decreases in gross margin were primarily due to the addition of newer offerings, some of which have shorter shipping cadences that impact the timing of revenue recognition and increase fulfillment costs.”
See the full cited Business Model analysis of Hims & Hers Health, Inc. Class A Common Stock
Where does growth come from?
Subscriber growth remains strong and is accelerating in absolute additions. Subscribers increased from approximately 1.426 million at Q3 2023 to 2.047 million at Q3 2024, a gain of 621,000 or 44%. The filing attributes growth to newer offerings, higher platform traffic, marketing, and improved onboarding. The document provides two quarter-end observations, so the direction is based on the latest year-over-year trajectory rather than a full sequential-quarter series. (1 accelerating, 1 decelerating, 1 new trend, 2 steady across 5 signals)
“Subscribers grew 19% to approximately 2.9 million as of June 30, 2026 as compared to approximately 2.4 million Subscribers as of June 30, 2025. Growth in Subscribers was primarily driven by increased traffic to our platform... our recent acquisition of Eucalyptus and improved onsite and customer onboarding experiences.”
Revenue per subscriber increased strongly to $84 per month in Q1 FY25, up 53% year over year. This is below the supplied prior-quarter level of $92 and indicates the monetization boost from weight-loss offerings may be normalizing. (1 decelerating, 1 new trend, 1 reversing across 3 signals)
“Monthly Revenue per Average Subscriber increased $16 to $92 for the three months ended June 30, 2026 as compared to $76 for the three months ended June 30, 2025... These increases were primarily due to changes in product mix, including uptake of our weight loss offerings.”
Gross margin declined to 76% in Q2 FY25 from 81% in Q2 FY24 and to 75% for H1 FY25 from 82% for H1 FY24. This is a clear negative reversal in the profitability trajectory despite strong revenue growth. Management attributes the pressure to newer GLP-1 offerings, which carry higher product, packaging, and shipping costs, while expecting margins to stabilize over time. (2 reversing, 3 decelerating across 5 signals)
“Our gross margin is expected to remain below comparative periods in the near term, primarily as a result of the 2026 US WL Announcement and recent international acquisitions. While we expect our gross margin to fluctuate from period to period... over the long term we expect gross margin to stabilize as we continue to scale our business and increase our ability to negotiate and optimize more favorable costs of revenue, as well as integrate new acquisitions.”
Regulatory pressure on compounded GLP-1 medicines is the largest identified growth constraint. The FDA said it intended to restrict certain active ingredients used in mass-marketed compounded GLP-1 products, and HHS referred the company to the DOJ. Hims & Hers responded by shifting toward branded GLP-1 medicines and limiting compounded offerings, creating risk of customer loss, lower conversion, supply disruption, and higher costs.
“In February 2026, the FDA issued a statement indicating that the agency intends to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed as similar alternatives to FDA-approved drugs. We were directly named in the FDA Statement... In March 2026, we announced a strategic shift for our U.S. weight loss offering... offering access to compounded GLP-1 products through the platform on a limited scale.”
No supporting data for the supplied Hers-share signal appears in this 2024 Q3 10-Q. The filing discusses Hims & Hers offerings and five specialties, but it does not report Hers as more than 40% of U.S. revenue or provide the cited 35% comparison. This signal cannot be assigned a multi-quarter trend from this document. (3 new trend, 2 discontinued across 5 signals)
“The filing describes the platform and its specialties but does not provide the supplied Hers revenue-share figures.”
See the full cited Future Growth analysis of Hims & Hers Health, Inc. Class A Common Stock
What could break the thesis?
The risk is currently stable to mildly intensifying. Subscribers increased 21% to 2.47 million and monthly online revenue per average subscriber increased 19% in Q3, indicating strong current demand. However, wholesale revenue declined 3% for nine months, management expects monthly revenue per subscriber to normalize over time, and weight loss may introduce seasonality. Approximately 70% of online revenue came from personalized offerings, which are more exposed to product availability and regulatory changes. The filing does not yet quantify customer losses from the post-shortage GLP-1 transition. (1 stable, 3 intensifying, 1 high-severity)
“Customers who previously accessed compounded alternatives may be unwilling or unable to transition to branded therapies, which could adversely affect demand, conversion rates, and revenue. In addition, our margins may be impacted by the cost of procuring branded medications and limitations on our ability to pass through price increases.”
The company is expanding pharmacies, laboratory testing, peptide manufacturing, and fulfillment facilities while it is still learning to operate some of these activities. Delays, failed batches, licensing problems, or cost overruns could reduce capacity and require additional capital. [EXECUTION]
“Assets not placed in service $246,454 ... Total property, equipment, and software, net $364,215.”
Clinician recruitment and retention are an execution risk. If affiliated medical groups cannot maintain enough qualified doctors, nurse practitioners, physician assistants, and behavioral-health providers, consultations may slow and customer satisfaction and revenue may suffer. [EXECUTION]
“If the Affiliated Medical Groups are unable to recruit and retain licensed physicians and other qualified Providers to perform services on our platform, it could have a material adverse effect on our business and ability to grow and could adversely affect our results of operations.”
The risk is emerging and HIGH. The company issued $1.0 billion of 0% convertible notes due 2030, increasing total liabilities substantially. The notes are unsecured and may be settled in cash, shares, or a combination. Based on the initial conversion price, the notes could represent approximately 14.15 million shares before considering capped-call protection. The company has no financial covenants on the notes, but a future fundamental change could require cash repurchase and a stock-price decline could make refinancing or repayment more difficult. (1 emerging, 1 stable, 1 intensifying, 1 high-severity)
“As of June 30, 2026, we had $12.6 million in letters of credit outstanding under our revolving credit facility sub-limit and $1.4 billion principal amount of indebtedness under the Convertible Notes.”
The risk is intensifying in the latest quarter despite strong revenue growth. For the first nine months, revenue increased 74%, while operating expenses increased 57%; however, in Q3 operating expenses increased 46% versus 49% revenue growth and operating income fell 47% to $11.8 million. Net income fell 79% year over year in Q3, partly because the prior-year period benefited from a large tax benefit, but the operating result itself deteriorated. Technology and development rose 97% and general and administrative expense rose 64% for nine months. (1 intensifying, 1 stable, 1 high-severity)
“Total operating expenses were $577,995 for the three months ended June 30, 2026, compared to $389,473 for the three months ended June 30, 2025, an increase of 48%. (Loss) income from operations was (97,192) for the three months ended June 30, 2026.”
See the full cited Risk analysis of Hims & Hers Health, Inc. Class A Common Stock
Hims & Hers Health, Inc. Class A Common Stock analysis by filing period
Read the full thesis on Hims & Hers Health, Inc. Class A Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.